Hospital-Acquired Infection Diagnostics Market Prediction

Hospital-Acquired Infection Diagnostics Market Research, 2030

The global hospital-acquired infection diagnostics market was valued at $3.4 billion in 2020, and is projected to reach $7.0 billion by 2030, growing at a CAGR of 7.6% from 2021 to 2030.

Hospital-acquired infections are infections caused by bacterial, viral, or fungal pathogens. In clinical settings, such as a nursing home, rehabilitation center, outpatient clinic, or other therapeutic settings, many infections can be acquired. They can be obtained through an infected patient, the outside environment, or the staff of that facility. Infections acquired in the hospital are a risk for all patients.

Hospital acquired infections are more common in people who have had surgery, the elderly, and children. Respiratory infections, surgical-site infections, gastrointestinal infections, urinary tract infections, bloodstream infections, cardiovascular system infections, and bone &joint infections are among the most prevalent infections. Hospital acquired diseases occur worldwide, affecting both developed and developing countries, and are important causes of death among hospitalized patients.

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 as a pandemic and general wellbeing crisis of international concern. COVID-19 has impacted around 210 countries across the globe. Owing to the COVID-19 pandemic, state-run administrations across the globe declared inescapable lockdowns as well as friendly distancing measures to forestall breakdown of the healthcare structure. States have additionally given constraints and preventions on undertakings and elective surgeries. These obstructions continue to influence the growth of different industries, and the enhanced response toward these regulations affects the industry. The distribution, production, and store network have been impacted, due to lockdowns across the globe.

Similarly, the hospital acquired infection diagnostics market had a positive impact during the pandemic, which has attributed to the surge in hospitalized patients and infectious virus contaminating the globe due to which the risk of hospital acquired infections increased. In addition, to accommodate the risk of infections, the demand for hospital acquired infection diagnostics products increased. Hence, overall the pandemic had a positive impact on hospital acquired infections diagnostics market.

The hospital-acquired infection diagnostics market is segmented into Product, Test Type, Application, Infection Type and End User.

The growth of hospital-acquired infection diagnostics market share is driven by surge in the prevalence of hospital acquired infections, increased awareness about hospital acquired infections, improved health care infrastructure, increased R&D spending, technological advancements, and increased government initiatives. However, a key restriction on the global market is lack of awareness regarding hospital acquired diseases in low and middle income nations. The market is primarily driven by rise in incidences of infections caused in clinical settings, especially in developing economies owing to their poor hygiene facilities. However, during hospital-acquired infection diagnostics market forecast the decline in hospital-acquired infections in the developed countries, such as U.S., Germany, and UK impedes the hospital-acquired infection diagnostics market growth.

The hospital-acquired infection diagnostics market size is segmented on the basis of product, test type, application, infection type, end user, and region. By product, the industry is split into instrument &reagents and consumables. By test type, the market is classified into molecular diagnostics, urinalysis, and immunoassay. By application type, the market is fragmented into disease testing and drug resistance testing.

Furthermore, on the basis of infection type, hospital-acquired infection diagnostics market size is classified into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. Its end users include hospitals, clinics, ambulatory surgery centres (ASC), and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.